Illumina introduces new DNA sequencing instruments, but Street unimpressed [Seeking Alpha]
10x Genomics, Inc. (TXG)
Last 10x genomics, inc. earnings: 2/18 04:01 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
i100 and MiSeq i100 Plus Systems, yet Street analysts appear to have been disappointed. Key features of the new systems include: room-temperature shipping and storage for reagents; run times as fast as four hours, providing same-day results four times faster than MiSeq; and 18 end-to-end workflows across 10 applications. Leerink analyst Puneet Souda, who rates Illumina outperform, wrote that "heading into ILMN's webinar there was investor speculation of a single cell instrument launch, which did not materialize," adding that this not happening could benefit shares of 10x Genomics ( TXG Canaccord Genuity's Kyle Mikson was similarly unimpressed. "Although we view the company's new low-throughput instrument positively, we are not convinced this relatively minor update will translate to improved financial performance in the near term." The product event was teased on Oct. 2, even though no details were provided, leading to Illumina to close up ~8% that day. More on Illumina Re
Show less
Read more
Impact Snapshot
Event Time:
TXG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXG alerts
High impacting 10x Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
TXG
News
- 10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Morgan Stanley from $28.00 to $26.00. They now have an "overweight" rating on the stock.MarketBeat
- 10x Genomics, Inc. (NASDAQ: TXG) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.MarketBeat
- 10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $20.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- 10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Citigroup Inc. from $23.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- 10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at JPMorgan Chase & Co. from $14.00 to $12.00. They now have a "neutral" rating on the stock.MarketBeat
TXG
Earnings
- 2/12/25 - Miss
TXG
Sec Filings
- 2/13/25 - Form S-8
- 2/13/25 - Form 10-K
- 2/12/25 - Form 8-K
- TXG's page on the SEC website